Hartej Gill

Researcher in mood disorders psychopharmacology at the University of Toronto / University Health Network

Data updated

Papers

8 publications

Trials

0 clinical trials

Research Footprint

Hartej Gill appears in 8 tracked papers (2020–2023), most studied alongside Ketamine, Psilocybin and MDMA, across Depressive Disorders, Anxiety Disorders and Major Depressive Disorder (MDD).

Most-cited paper: Real-world effectiveness of ketamine in treatment-resistant depression: A systematic review & meta-analysis (169 citations).

Frequent co-authors: Roger McIntyre, Jonathan Rosenblat and Maria Rodrigues.

Background & Research

Hartej Gill is a researcher associated with the Mood Disorders Psychopharmacology Unit at the University Health Network and the University of Toronto in Toronto, Canada. Their publications include systematic reviews and meta-analyses on ketamine’s antidepressant, antisuicidal, and cognitive effects, as well as work on registered clinical studies of psychedelic drugs for psychiatric disorders. Recent article listings identify Gill as a corresponding author on this research program.

Key Impact

Notable for coauthoring multiple reviews and meta-analyses on ketamine, esketamine, suicidality, cognition, and psychedelic drug trials in psychiatric research.

8

Research Papers

View publications →

0

Clinical Trials

Explore trials →

Collaboration Network

18 collaborators· click a node to visit their profile

Full network →

Collaboration Network

See Hartej Gill's full collaboration network, shared papers, and research connections.

Compounds

Ketamine5Psilocybin3MDMA2Esketamine1

Topics

Depressive Disorders8Anxiety Disorders5Major Depressive Disorder (MDD)5Treatment-Resistant Depression (TRD)4Suicidality3Bipolar Disorder3Safety & Risk Management2PTSD2Equity and Ethics1Adolescents1Neurocognitive Disorders1Schizophrenia1Borderline Personality Disorder (BPD)1Personality Disorders1Alcohol Use Disorder (AUD)1Substance Use Disorders (SUD)1Neuroimaging & Brain Measures1Healthy Volunteers1Medicinal Chemistry & Drug Development1Obsessive-Compulsive Disorder (OCD)1

Top Collaborators

Top Collaborators

Unlock clinical summaries, full texts, and related trial mapping.

Affiliations

Institutions, companies, and organisations Hartej Gill is associated with.

University of Toronto

University of Toronto is a leading Canadian research university whose psychedelic and psychiatric research spans the Department of Psychiatry, University Health Network collaborations, and specialized clinical units including mood-disorders psychopharmacology programs.

View stakeholder →

Brain and Cognition Discovery Foundation

Non-Profit

Canada-based foundation backing translational and clinical research programs in mental health, including psychedelic-relevant workstreams.

View stakeholder →